SA518391109B1 - Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ - Google Patents
Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـInfo
- Publication number
- SA518391109B1 SA518391109B1 SA518391109A SA518391109A SA518391109B1 SA 518391109 B1 SA518391109 B1 SA 518391109B1 SA 518391109 A SA518391109 A SA 518391109A SA 518391109 A SA518391109 A SA 518391109A SA 518391109 B1 SA518391109 B1 SA 518391109B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- cell receptors
- mutated kras
- mammal
- hla
- disclosed
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 3
- 102100030708 GTPase KRas Human genes 0.000 abstract 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 abstract 1
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Abstract
يتعلق الاختراع الحالي بمستقبل خلية تائية T cell receptor (TCR) معزولة ومنقاة له خصوصية مستضدة لتماثل جين فيروسي ورمي ساركومي sarcoma viral oncogene homolog لفأر Kirsten (KRAS) المطفر المقدم في سياق جزيء Cw*0802 لمستضد كريات بيضاء بشرية human leukocyte antigen (HLA).تم توفير بولي بيبتيدات polypeptide وبروتينات proteins ذات صلة بالإضافة إلى أحماض نووية nucleic acids ذات صلة وناقلات تعبير إعادة الاتحاد وخلايا مضيفة host cells وتجميعات خلوية وتركيبات صيدلانية.تم أيضًا الكشف عن طرق لاكتشاف وجود السرطان cancer في الثدييات mammal وطرق معالجة السرطان والوقاية منه في الثدييات.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562218688P | 2015-09-15 | 2015-09-15 | |
PCT/US2016/050875 WO2017048593A1 (en) | 2015-09-15 | 2016-09-09 | T cell receptors recognizing hla-cw8 restricted mutated kras |
Publications (1)
Publication Number | Publication Date |
---|---|
SA518391109B1 true SA518391109B1 (ar) | 2022-02-14 |
Family
ID=56985686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SA518391109A SA518391109B1 (ar) | 2015-09-15 | 2018-03-13 | Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ |
Country Status (15)
Country | Link |
---|---|
US (3) | US10556940B2 (ar) |
EP (2) | EP3901169A1 (ar) |
JP (2) | JP7185524B2 (ar) |
KR (1) | KR20180044428A (ar) |
CN (2) | CN115073583A (ar) |
AU (3) | AU2016323017B2 (ar) |
CA (1) | CA2998869A1 (ar) |
DK (1) | DK3350213T3 (ar) |
ES (1) | ES2879287T3 (ar) |
HK (1) | HK1257902A1 (ar) |
IL (1) | IL257840B2 (ar) |
MX (1) | MX2018003062A (ar) |
SA (1) | SA518391109B1 (ar) |
SG (1) | SG10201913868XA (ar) |
WO (1) | WO2017048593A1 (ar) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7409773B2 (ja) | 2015-07-31 | 2024-01-09 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 改変された細胞および治療の方法 |
IL264425B2 (en) * | 2016-08-02 | 2023-09-01 | Us Secretary Department Of Health And Human Services | t cell receptors against kras-g20 |
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
US11898207B2 (en) | 2017-03-31 | 2024-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating neoantigen-specific T cell receptor sequences |
CN111406068A (zh) * | 2017-05-16 | 2020-07-10 | 约翰霍普金斯大学 | MANAbody及使用方法 |
WO2019006418A2 (en) | 2017-06-30 | 2019-01-03 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
AU2018335274A1 (en) * | 2017-09-20 | 2020-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class II–restricted T cell receptors against mutated RAS |
CA3084246A1 (en) * | 2017-12-04 | 2019-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against mutated ras |
US20210268091A1 (en) * | 2018-06-19 | 2021-09-02 | Biontech Us Inc. | Neoantigens and uses thereof |
AU2019321608A1 (en) * | 2018-08-16 | 2021-03-18 | Biontech Us Inc. | T cell receptor constructs and uses thereof |
WO2020154275A1 (en) * | 2019-01-22 | 2020-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted t cell receptors against ras with g12r mutation |
GB2613715B (en) | 2019-02-20 | 2023-12-06 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
WO2020210202A1 (en) * | 2019-04-11 | 2020-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer |
CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
CN112110995A (zh) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | 肿瘤新抗原多肽及其用途 |
CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术(广东)有限公司 | 一种识别Kras G12V的高亲和力TCR |
CA3164986A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
CN111574616B (zh) * | 2020-06-17 | 2021-02-02 | 深圳豪石生物科技有限公司 | 分离的t细胞受体和应用 |
WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
CN114920824B (zh) * | 2022-05-27 | 2023-12-05 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
HUE038833T2 (hu) * | 2005-08-05 | 2018-11-28 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Antigénspecifikus T-sejtek létrehozása |
US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
ME02810B (me) * | 2010-09-20 | 2018-01-20 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t ćelijski receptori i t ćelijski epitopi |
US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
SI2755997T1 (sl) | 2011-09-15 | 2018-11-30 | The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage |
GB201314404D0 (en) | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
JP6863893B2 (ja) | 2014-11-26 | 2021-04-21 | アメリカ合衆国 | 抗突然変異kras t細胞受容体 |
-
2016
- 2016-09-09 CN CN202111083392.9A patent/CN115073583A/zh active Pending
- 2016-09-09 EP EP21162567.8A patent/EP3901169A1/en active Pending
- 2016-09-09 EP EP16770408.9A patent/EP3350213B1/en active Active
- 2016-09-09 JP JP2018513423A patent/JP7185524B2/ja active Active
- 2016-09-09 IL IL257840A patent/IL257840B2/en unknown
- 2016-09-09 US US15/758,954 patent/US10556940B2/en active Active
- 2016-09-09 DK DK16770408.9T patent/DK3350213T3/da active
- 2016-09-09 SG SG10201913868XA patent/SG10201913868XA/en unknown
- 2016-09-09 MX MX2018003062A patent/MX2018003062A/es unknown
- 2016-09-09 AU AU2016323017A patent/AU2016323017B2/en active Active
- 2016-09-09 CN CN201680058891.3A patent/CN108350059B/zh active Active
- 2016-09-09 CA CA2998869A patent/CA2998869A1/en active Pending
- 2016-09-09 WO PCT/US2016/050875 patent/WO2017048593A1/en active Application Filing
- 2016-09-09 KR KR1020187010326A patent/KR20180044428A/ko not_active Application Discontinuation
- 2016-09-09 ES ES16770408T patent/ES2879287T3/es active Active
-
2018
- 2018-03-13 SA SA518391109A patent/SA518391109B1/ar unknown
-
2019
- 2019-01-08 HK HK19100263.9A patent/HK1257902A1/zh unknown
-
2020
- 2020-01-10 US US16/739,310 patent/US11667692B2/en active Active
-
2021
- 2021-02-10 AU AU2021200833A patent/AU2021200833B2/en active Active
-
2022
- 2022-07-26 AU AU2022209229A patent/AU2022209229B2/en active Active
- 2022-11-25 JP JP2022188263A patent/JP7461445B2/ja active Active
-
2023
- 2023-05-01 US US18/310,141 patent/US20230406904A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11667692B2 (en) | 2023-06-06 |
CN108350059B (zh) | 2021-10-08 |
JP7461445B2 (ja) | 2024-04-03 |
JP2018535647A (ja) | 2018-12-06 |
ES2879287T3 (es) | 2021-11-22 |
IL257840B2 (en) | 2023-10-01 |
CN115073583A (zh) | 2022-09-20 |
US10556940B2 (en) | 2020-02-11 |
AU2016323017A1 (en) | 2018-04-05 |
CA2998869A1 (en) | 2017-03-23 |
EP3350213A1 (en) | 2018-07-25 |
CN108350059A (zh) | 2018-07-31 |
WO2017048593A1 (en) | 2017-03-23 |
AU2016323017B2 (en) | 2020-11-12 |
MX2018003062A (es) | 2018-09-11 |
HK1257902A1 (zh) | 2019-11-01 |
KR20180044428A (ko) | 2018-05-02 |
EP3350213B1 (en) | 2021-03-31 |
EP3901169A1 (en) | 2021-10-27 |
US20190040111A1 (en) | 2019-02-07 |
IL257840A (en) | 2018-04-30 |
JP7185524B2 (ja) | 2022-12-07 |
AU2022209229A1 (en) | 2022-09-15 |
AU2021200833B2 (en) | 2022-04-28 |
JP2023025108A (ja) | 2023-02-21 |
AU2022209229B2 (en) | 2024-05-23 |
AU2021200833A1 (en) | 2021-03-04 |
IL257840B1 (en) | 2023-06-01 |
DK3350213T3 (da) | 2021-06-21 |
SG10201913868XA (en) | 2020-03-30 |
US20200148739A1 (en) | 2020-05-14 |
US20230406904A1 (en) | 2023-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA518391109B1 (ar) | Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ | |
MX2020003117A (es) | Receptores de celulas t restringidas a hla de clase ii contra ras mutado. | |
MX2017006865A (es) | Receptores de células t de kras anti-mutado. | |
CR20200170A (es) | Receptores de células t que reconocen p53 mutado | |
MX2020005765A (es) | Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado. | |
AU2019283892A1 (en) | Anti-human papillomavirus 16 E7 T cell receptors | |
MX2019009641A (es) | Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida. | |
CA2848209C (en) | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage | |
CY1124176T1 (el) | Προβλεψη ανοσογονiκοτητας των επιτοπων των t κυτταρων | |
MX2020009472A (es) | Receptores de antigenos quimericos anti-cd33 y sus usos. | |
MX2021015877A (es) | Receptores de celulas t que reconocen la mutacion r175h o y220c en p53. | |
MX2023002858A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
MX2019003445A (es) | Proteinas de fusion inmunomoduladoras. | |
MX2018004503A (es) | Receptores de antigeno quimerico anti-cd30. | |
PH12018501335A1 (en) | Novel generation of antigen-specific tcrs | |
MX358711B (es) | Inmunogenos para vacunacion contra vih. | |
MX2018012550A (es) | Composiciones y metodos para la deteccion de proteinas de celulas huesped. | |
MX2022007902A (es) | Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia. | |
MX2022010157A (es) | Receptores de células t restringidos a hla clase ii contra ras con mutación g12v. | |
MX2022009825A (es) | Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v. | |
TR201905447T4 (tr) | Yeni mhc bağımsız tümörle ilişkili antijenler. | |
WO2016029125A8 (en) | Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer | |
IN2014DN09963A (ar) | ||
MX2018003445A (es) | Expresion de proteinas que contienen fc. | |
WO2016077525A3 (en) | Human anti-thyroglobulin t cell receptors |